Pfizer vs Merck: Chasing High Yield vs Higher Returns

20 hours ago 3

Vandita Jadeja

Wed, June 3, 2026 astatine 9:06 AM CDT 3 min read

Quick Read

PFE yields 6.58% astatine a guardant P/E of 9, portion MRK surged 61% implicit the past twelvemonth with a acold smaller payout.
KEYTRUDA drives astir fractional of Merck's pharma revenue, making its biosimilar patent cliff the ascendant hazard heading into 2027.
Pfizer's $7 cardinal Metsera woody pushes into obesity, and CEO Albert Bourla is directing currency toward dividends implicit buybacks.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Merck wasn't 1 of them. Get them present FREE.

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) some conscionable closed net chapters that framework the 2026 dividend statement clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 study dominated by a $9 cardinal Cidara acquisition charge. Two precise antithetic income stories for output hunters.

One Pays You to Wait. One Pays You to Believe.

Pfizer is present a 6.58% yielder, distributing $9.8 cardinal successful 2025 dividends astatine $1.72 per share. That payout sits connected a $3.22 adjusted EPS base, truthful sum looks comfy adjacent with COVID gross fading. Non-COVID maturation told the existent story: Abrysvo jumped 136%, Eliquis added 10%, and oncology biosimilars surged 77%.

Merck pays a smaller output of 2.74% connected a $3.28 yearly dividend, but the underlying concern is increasing faster. KEYTRUDA delivered $8.03 cardinal successful Q1 2026, up 12%, portion WINREVAIR rocketed 88% to $525 million. Animal Health added a dependable 13%. The caller quarterly dividend bump from $0.81 to $0.85 signals confidence.

Lens	Pfizer	Merck
Dividend Yield	6.58%	2.74%
Forward P/E	9	23
1-Year Stock Return	19.48%	61.04%

Yield Hunter vs. Pipeline Believer

Pfizer is reshaping itself done M&A. CEO Albert Bourla told investors "2026 volition beryllium an important twelvemonth affluent successful cardinal catalysts, including our anticipation for astir 20 cardinal pivotal survey starts".

The $7 cardinal Metsera bargain pushes Pfizer into obesity, and absorption is chasing $7.2 cardinal successful nett outgo savings by 2027. Buybacks stay disconnected the table, which I work arsenic a cleanable awesome that the dividend is the priority.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Merck wasn't 1 of them. Get them present FREE.

Merck is gathering a post-KEYTRUDA portfolio with urgency. The Cidara woody closed, Terns is pending astatine astir $5.8 billion, and Verona Pharma already contributed $131 cardinal successful Q1. The risk: GARDASIL gross successful China fell 47%, and involvement disbursal climbed to $479 million. Faster growth, heavier balance-sheet lifting.

The Next Test Is Patent Defense

For Pfizer, I volition beryllium watching whether Metsera's ultra-long-acting GLP-1 candidates tin credibly vie with Novo and Lilly. The $1.5 cardinal loss-of-exclusivity headwind successful 2026 is manageable, but obesity execution is the plaything factor.

Read Entire Article